Soc. Generale Knock-Out MRK 21.06.../ DE000SU630U7 /
03/06/2024 08:57:48 | Chg.0.00 | Bid13:02:29 | Ask13:02:29 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
9.60EUR | 0.00% | 9.80 Bid Size: 6,000 |
10.00 Ask Size: 6,000 |
MERCK KGAA O.N. | - EUR | 21/06/2024 | Call |
GlobeNewswire
14:00
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX...
GlobeNewswire
02:38
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pe...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA